SRTS
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number N/A; valuation is disconnected from current earnings reality.
- P/B is relatively low at 1.54
- Forward P/E of 70.90 is excessive for a shrinking company
- Negative profit margins
Growth metrics are in a state of freefall.
- Analyst target price of $6.88 suggests potential upside
- Revenue growth is -62.20%
- EPS growth is -311.1%
Historical performance shows a sharp decline in profitability over the last 4 quarters.
- Occasional earnings beats in 2024
- Recent trend of massive earnings misses
- Negative ROE and ROA
Strong balance sheet (liquidity) but failing operational health (F-Score).
- Near-zero debt
- Very high quick ratio (5.96)
- Piotroski F-Score of 2/9 indicates poor financial health
Dividend Yield: N/A
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SRTS and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
Primary
|
+32.1% | -14.0% | -2.2% | +40.3% | +16.6% | 0.0% |
|
HCAT
Health Catalyst, Inc.
Peer
|
-98.0% | -92.3% | -74.0% | -62.4% | -46.4% | -14.8% |
|
ASRT
Assertio Holdings, Inc.
Peer
|
-80.4% | -85.9% | -2.8% | -7.5% | -1.3% | -1.5% |
|
LNSR
LENSAR, Inc.
Peer
|
-17.5% | +119.2% | -57.5% | -52.1% | -51.6% | -5.9% |
|
OM
Outset Medical, Inc.
Peer
|
-99.5% | -98.4% | -61.8% | -67.9% | +29.9% | +3.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
|
BEARISH | $73.91M | - | -14.9% | -28.1% | $4.49 | |
|
HCAT
Health Catalyst, Inc.
|
BEARISH | $73.31M | - | -58.3% | -57.2% | $1.0 | Compare |
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $74.82M | - | -24.5% | -21.1% | $11.66 | Compare |
|
LNSR
LENSAR, Inc.
|
BEARISH | $68.95M | - | -1069.4% | -58.7% | $5.7 | Compare |
|
OM
Outset Medical, Inc.
|
BEARISH | $79.66M | - | -106.2% | -68.3% | $4.35 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | SACHETTA ERIC | Director | Purchase | 2,000 | $7,620 |
| 2025-12-12 | SARDANO MICHAEL | President | Stock Award | 40,000 | - |
| 2025-11-21 | SACHETTA ERIC | Director | Purchase | 7,000 | $27,510 |
| 2025-11-18 | SARDANO MICHAEL | President | Purchase | 1,000 | $3,800 |
| 2025-11-18 | SARDANO JOSEPH C | Chief Executive Officer | Purchase | 25,000 | $100,750 |
| 2025-11-13 | SACHETTA ERIC | Director | Purchase | 2,500 | $11,250 |
| 2025-11-11 | SARDANO MICHAEL | President | Purchase | 1,000 | $4,260 |
| 2025-11-11 | SARDANO MICHAEL | President | Purchase | 2,000 | $8,523 |
| 2025-11-11 | SARDANO MICHAEL | President | Purchase | 2,000 | $8,546 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SRTS from our newsroom.